Kyverna Therapeutics (NASDAQ: KYTX) reported a second-quarter 2026 net loss per share of $(0.63), beating analyst consensus of $(0.68) by 7.35 percent while narrowing its year-over-year loss by 35 percent from $(0.97). The results coincide with the U.S. Food and Drug Administration granting Regenerative Medicine Advanced Therapy (RMAT) designation for its lead candidate, miv-cel, in non-active secondary progressive multiple sclerosis (naSPMS). This dual progress in financial discipline and regulatory advancement strengthens Kyverna’s position as it prepares for potential commercial launch of its CAR T-cell therapy franchise.

The company reported total operating expenses of $39.6 million for the quarter, driven by research and development (R&D) costs of $24.8 million and general and administrative (G&A) expenses of $14.8 million. These figures represent a reduction from the prior-year period, where R&D expenses stood at $35.8 million and G&A at $8.6 million, indicating a strategic shift in spending allocation toward late-stage development and commercial readiness activities. Warner Biddle, Chief Executive Officer, highlighted that the company is advancing commercial launch readiness for stiff person syndrome (SPS) while accelerating enrollment in its generalized myasthenia gravis (gMG) trial.

Key Financial Metrics

Pipeline and Regulatory Progress

The FDA’s RMAT designation for miv-cel in naSPMS is based on compelling clinical data from investigator-initiated trials at Stanford University and the University of California, San Francisco. This designation provides eligibility for priority and rolling reviews, potentially accelerating approval pathways. Kyverna expects to provide an update on its progressive multiple sclerosis development strategy by early 2027, with additional data from the Stanford Phase 1 trial anticipated in the fourth quarter of 2026.

Simultaneously, Kyverna has initiated its rolling Biologic License Application (BLA) submission for miv-cel in SPS, having already submitted the Chemistry, Manufacturing, and Controls module. The company aims to complete this submission in the fourth quarter of 2026, positioning miv-cel for potential commercial launch in 2027 under priority review. Enrollment in the Phase 3 registrational trial for gMG is ongoing, with completion expected by mid-2027. Longer-term follow-up Phase 2 data for gMG is scheduled for release in the third quarter of 2026.

What the Numbers Show

The contraction in net loss per share from $(0.97) to $(0.63) underscores improved operational efficiency, despite an increase in G&A expenses related to commercial build-out. The significant reduction in R&D spend, down from $35.8 million to $24.8 million, suggests that major clinical milestones may have been met or deferred, allowing for better cash preservation. With $199.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026, Kyverna maintains an operating runway into 2028, providing ample time to navigate the final stages of regulatory approval and initial commercialization without immediate dilutive financing needs.

Leadership changes also marked the quarter, with the appointments of Greg Martini as Chief Financial Officer, Nadia Dac as Chief Commercial Officer, and Ritesh Srivastava as Chief Legal and Compliance Officer. These hires signal Kyverna’s transition from a purely clinical-stage entity to one preparing for market entry, reinforcing management’s confidence in the near-term viability of its SPS indication.

Kyverna Therapeutics, Inc. (NASDAQ: KYTX) has appointed Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026, to strengthen its leadership team as it advances miv-cel (mivocabtagene autoleucel, KYV-101) towards potential approval in stiff person syndrome and transitions to a commercial-stage organization. Srivastava brings extensive experience spanning legal, corporate strategy, compliance, and risk management, which will support Kyverna's next phase of growth.

Leadership Background

Srivastava joins Kyverna from BPGbio, where he served as General Counsel, providing legal and strategic counsel across research and development, commercialization planning, and business operations. Prior to BPGbio, he was Global Compliance Officer at Spectrum Pharmaceuticals, advising the Board of Directors on corporate governance, risk management, and public company disclosure matters. Earlier, he served as Director of Compliance and Investigations at Avanir Pharmaceuticals.

A former federal prosecutor with the United States Department of Justice, Srivastava led law enforcement teams in investigating and prosecuting healthcare fraud and anti-kickback matters. He began his career as an officer with the Navy’s Judge Advocate General Corps, serving for six years as a trial defense lawyer and later as Appellate Government Counsel, achieving the rank of Lieutenant Commander. He holds a Juris Doctor from Pepperdine University School of Law and a Bachelor of Science from Columbia University.

Inducement Grant Details

In connection with his appointment, Kyverna granted Srivastava an option to purchase 260,000 shares of its common stock. The option was granted pursuant to the Kyverna Therapeutics, Inc. Amended and Restated 2024 Inducement Equity Incentive Plan as an inducement material to his employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price will be the closing price of Kyverna's common stock on the date of grant.

Strategic Focus

Warner Biddle, Chief Executive Officer of Kyverna, emphasized Srivastava's role in the company's commercialization efforts. "Ritesh’s experience in corporate governance, regulatory compliance, business and financial transactions, and legal operations at commercial-stage organizations will be invaluable as we advance our multi-indication neuroimmunology franchise," Biddle said.

Srivastava highlighted Kyverna's progress with miv-cel, noting the initiation of the first Biologics License Application (BLA) submission for an autoimmune CAR T-cell therapy. "This is an exciting time to join the company, whose mission represents a meaningful opportunity to advance potentially curative treatments for patients while supporting the company’s strategic priorities and long-term growth," he said.